Anaphylaxis News and Research

RSS
Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.
Dyax announces first Phase 3 trial results of KALBITOR for acute HAE

Dyax announces first Phase 3 trial results of KALBITOR for acute HAE

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Xeomin receives FDA approval for treatment of cervical dystonia

Xeomin receives FDA approval for treatment of cervical dystonia

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Dyax second-quarter total revenues increase to $15.1 million

Dyax second-quarter total revenues increase to $15.1 million

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

AANMA recommends a written asthma action plan before child self-medication

AANMA recommends a written asthma action plan before child self-medication

Dyax launches newly enhanced product website featuring comprehensive financial assistance program

Dyax launches newly enhanced product website featuring comprehensive financial assistance program

GTC Biotherapeutics regains US commercialization rights to ATryn from Lundbeck

GTC Biotherapeutics regains US commercialization rights to ATryn from Lundbeck

First-of-its-kind patient, healthcare provider support program for management of HE

First-of-its-kind patient, healthcare provider support program for management of HE

NIH announces 5 more years of funding for Consortium of Food Allergy Research

NIH announces 5 more years of funding for Consortium of Food Allergy Research

Pfizer to present results of hemophilia studies at WFH 2010 Congress

Pfizer to present results of hemophilia studies at WFH 2010 Congress

FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy

FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Fraudulent Tamiflu sold over Internet, FDA warns

Fraudulent Tamiflu sold over Internet, FDA warns

Biogen, Elan launch My MS Health, a web-based PRO research program

Biogen, Elan launch My MS Health, a web-based PRO research program

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

EDEMA4 study results of KALBITOR for treatment of acute attacks of HAE published

EDEMA4 study results of KALBITOR for treatment of acute attacks of HAE published